ERBB2 and cancer: DESTINY-Pantumor-02 is an open-label, multi-cohort, multi-center phase II study that showed a benefit in ORR, PFS, DOR and OS thanks to the administration of T-DXd in 267 pre-treated patients affected by different types of HER2-expressing cancers such as bladder, endometrial, cervical, ovarian, biliary tract, pancreatic and other (except for gastric, breast, colorectal and non-small-cell lung cancers).